NewKerala.com

CDSCO Drug Alert: 112 Medicines Fail Quality Tests Amid Safety Concerns

The CDSCO has flagged 112 drug samples as not meeting standard quality requirements in September. Central laboratories identified 52 problematic samples while state facilities found 60 more. Authorities also discovered one spurious drug from Chattisgarh manufactured illegally using another company's brand name. This monthly surveillance program helps ensure unsafe medicines get removed from the market promptly.

Key Points: CDSCO Flags 112 Drug Samples as Not Standard Quality

  • Central labs identified 52 substandard drug samples in September testing
  • State testing laboratories found 60 additional NSQ drug samples
  • One spurious drug from Chattisgarh manufactured by unauthorized company
  • Monthly surveillance ensures prompt removal of unsafe medicines from market
2 min read

CDSCO flags 112 drug samples as 'not of standard quality' in September

Central drugs authority identifies 112 substandard medicines in September, including one spurious drug from Chattisgarh. Monthly surveillance ensures market safety.

"For the month of September 2025, Central Drugs Laboratories have identified 52 drug samples to be Not of Standard Quality - CDSCO Alert"

New Delhi, Oct 23

The Central Drugs Standard Control Organisation (CDSCO) on Thursday declared 112 drug samples tested by the Central and state drugs regulatory authorities as ‘Not of Standard Quality (NSQ)' in its monthly drug alert for September.

While 52 drug samples were identified by the Central Drugs Laboratories as NSQ, the State Drugs Testing Laboratories identified 60 drug samples as NSQ.

As per routine regulatory surveillance activity, the list of NSQ and spurious drugs is being displayed on the CDSCO portal on a monthly basis.

“For the month of September 2025, Central Drugs Laboratories have identified 52 drug samples to be Not of Standard Quality (NSQ) and State Drugs Testing Laboratories have identified 60 drug samples as Not of Standard Quality (NSQ),” the alert said.

Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters.

The failure is specific to the drug products of the batch tested by the government laboratory, and it does not warrant any concerns on the other drug products available in the market, the health officials said.

Further, in September, “one drug sample from Chattisgarh was identified as a spurious drug. It was manufactured by an unauthorised manufacturer using a brand name owned by another company. The matter is under investigation and action will be taken as per the Act & Rules,” they added.

The action of identifying NSQ and Spurious medicines is taken regularly in collaboration with state regulators to ensure that these drugs are identified and removed from the market.

The CDSCO declared 94 drug samples tested by the Central and state drugs regulatory authorities in the month of August as NSQ.

In August, the Central Drugs Laboratories identified 32 drug samples to be NSQ, while the State Drugs Testing Laboratories identified 62 drug samples as NSQ.

- IANS

Share this article:

Reader Comments

R
Rohit P
At least they're being transparent about the numbers and taking action. Better than hiding such information. The monthly alert system is a good step towards accountability.
D
David E
As someone who relies on regular medication for diabetes, this news makes me anxious. The spurious drug case from Chattisgarh is particularly alarming - fake manufacturers putting lives at risk for profit.
A
Ananya R
The increase from 94 NSQ drugs in August to 112 in September is worrying. Are the testing standards getting stricter or are manufacturers getting more careless? Either way, public health is at stake.
S
Sarah B
I appreciate that they're being specific that it's only particular batches and not all products from these companies. But still, we need better quality control across the pharmaceutical industry.
M
Manish T
While I support the regulatory action, I wish they would name the specific drugs and companies involved. Patients have the right to know exactly which medicines to avoid. Transparency should be complete.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50